Nurix Therapeutics, Inc. (NRIX) Revenue by Segment & Business Profile
License Revenue was 97.0% of Nurix Therapeutics, Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason
NRIXNurix Therapeutics, Inc.Follow NRIX — free
—
Price chart with a free account
- Market cap
- 2.8B
- P/E TTM
- 10.0
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 26 Jan, in 94 days
What the company does
Nurix Therapeutics, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: License Revenue (97%), Collaboration Revenue (3%). Trailing twelve-month revenue: $701.9 million as of 2026-08-31.
Roles we read
from the filings, not the sector label- Clinical-stage developer
Nurix Therapeutics, Inc. — questions
- What does Nurix Therapeutics, Inc. do?
- Nurix Therapeutics, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: License Revenue (97%), Collaboration Revenue (3%). Trailing twelve-month revenue: $701.9 million as of 2026-08-31.
- How does Nurix Therapeutics, Inc. make money?
- By the lines it reports in its SEC filings: License Revenue 97.0%, Collaboration Revenue 3.0% of revenue.
Every figure on this page comes from Nurix Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.